Product nameAnti-EIF2B5 antibody
See all EIF2B5 primary antibodies
DescriptionRabbit polyclonal to EIF2B5
Tested applicationsSuitable for: WB, IP, IHC-Pmore details
Species reactivityReacts with: Human
Synthetic peptide corresponding to Human EIF2B5 aa 400-450.
Database link: NP_003898.2
- HeLa and 293T whole cell lysates
This product was previously labelled as eIF2B epsilon
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage bufferPreservative: 0.09% Sodium azide
Constituent: Tris citrate/phosphate
Concentration information loading...
PurityImmunogen affinity purified
Purification notesab91565 was affinity purified using an epitope specific to EIF2B5 immobilized on solid support.
Our Abpromise guarantee covers the use of ab91565 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/2000 - 1/10000. Predicted molecular weight: 80 kDa.|
|IP||Use at 5-15 µg/mg of lysate.|
|IHC-P||1/500 - 1/2000. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.|
FunctionCatalyzes the exchange of eukaryotic initiation factor 2-bound GDP for GTP.
Involvement in diseaseDefects in EIF2B5 are a cause of leukodystrophy with vanishing white matter (VWM) [MIM:603896]. VWM is a leukodystrophy that occurs mainly in children. Neurological signs include progressive cerebellar ataxia, spasticity, inconstant optic atrophy and relatively preserved mental abilities. The disease is chronic-progressive with, in most individuals, additional episodes of rapid deterioration following febrile infections or minor head trauma. While childhood onset is the most common form of the disorder, some severe forms are apparent at birth. A severe, early-onset form seen among the Cree and Chippewayan populations of Quebec and Manitoba is called Cree leukoencephalopathy. Milder forms may not become evident until adolescence or adulthood. Some females with milder forms of the disease who survive to adolescence exhibit ovarian dysfunction. This variant of the disorder is called ovarioleukodystrophy.
Sequence similaritiesBelongs to the eIF-2B gamma/epsilon subunits family.
Contains 1 W2 domain.
- Information by UniProt
- CACH antibody
- CLE antibody
- EI2BE_HUMAN antibody
All lanes : Anti-EIF2B5 antibody (ab91565) at 0.1 µg/ml
Lanes 1 & 4 : HeLa whole cell lysate at 50 µg
Lane 2 : HeLa whole cell lysate at 15 µg
Lane 3 : 293T whole cell lysate at 5 µg
Developed using the ECL technique.
Predicted band size: 80 kDa
Exposure time: 30 seconds
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human ovarian carcinoma tissue labelling EIF2B5 with ab91565 at 1/1000 (1µg/ml). Detection: DAB.
Detection of EIF2B5 by Western Blot of Immunprecipitate.
ab91565, at 1 µg/ml, staining EIF2B5 in HeLa whole cell lysate immunoprecipitated using ab91565 at 10 µg/mg lysate (1 mg/IP; 20% of IP loaded/lane).
Detection: Chemiluminescence with exposure time of 10 seconds.
ab91565 has not yet been referenced specifically in any publications.